Business
Currency:USD
2024/Q2
Stock NameRevenueRatio
Coronavirus disease 2019 (COVID-19)18.94M34.86%
Human immunodeficiency virus (HIV)13.65M25.13%
Molecular Sample Management Solutions12.61M23.21%
Hepatitis C virus (HCV)4.73M8.71%
Risk assessment testing2.31M4.25%
Other product and service revenues897K1.65%
Molecular Services810K1.49%
Non-product and services revenues386K0.71%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States361.66M89.19%
Other regions35.7M8.80%
Europe8.11M2.00%
